The burden of tuberculosis (TB) remains significant globally, necessitating the development of innovative diagnostic strategies. The evolution of TB detection methods has been remarkable, ranging from traditional microscopy to advanced molecular techniques. This article aims to provide an overview of the current diagnostic strategies in TB detection.
The cornerstone of TB diagnosis for decades has been sputum smear microscopy and culture. These methods, while cost-effective, have limitations in sensitivity and specificity. Moreover, culture results take weeks, delaying timely diagnosis and treatment.
Over the past decade, molecular techniques have revolutionized TB detection. The WHO-endorsed Xpert MTB/RIF assay, a real-time PCR-based method, provides results within two hours and has superior sensitivity and specificity. It also detects rifampicin resistance, aiding in the management of drug-resistant TB.
Immunological tests like the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs) detect the immune response to Mycobacterium tuberculosis. While TST is prone to false positives due to BCG vaccination or non-tuberculous mycobacteria, IGRAs are more specific and can distinguish between latent and active TB.
Emerging technologies such as Next-Generation Sequencing (NGS) and breath tests show promise for future TB diagnostics. NGS can provide comprehensive genomic information, aiding in the detection of drug resistance. Breath tests, still in experimental stages, aim to detect volatile organic compounds associated with TB, offering a non-invasive diagnostic method.
The advancements in TB detection have significantly improved diagnostic accuracy and time, contributing to better patient outcomes. However, challenges remain in resource-limited settings. Continued research and investment in TB diagnostics are crucial to control this global health threat effectively.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation